Literature DB >> 34469203

Evaluation of G protein bias and β-arrestin 2 signaling in opioid-induced respiratory depression.

Jordan T Bateman1, Erica S Levitt1.   

Abstract

Respiratory depression is a potentially fatal side effect of opioid analgesics and a major limitation to their use. G protein-biased opioid agonists have been proposed as "safer" analgesics with less respiratory depression. These agonists are biased to activate G proteins rather than β-arrestin signaling. Respiratory depression has been shown to correlate with both G protein bias and intrinsic efficacy, and recent work has refuted the role of β-arrestin signaling in opioid-induced respiratory depression. In addition, there is substantial evidence that G proteins do, in fact, mediate respiratory depression by actions in respiratory-controlling brainstem neurons. Based on these studies, we provide the perspective that protection from respiratory depression displayed by newly developed G protein-biased agonists is due to factors other than G protein versus arrestin bias.

Entities:  

Keywords:  G protein; opioid; respiratory; β-arrestin

Mesh:

Substances:

Year:  2021        PMID: 34469203      PMCID: PMC8560383          DOI: 10.1152/ajpcell.00259.2021

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   5.282


  29 in total

Review 1.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

2.  Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics.

Authors:  Cullen L Schmid; Nicole M Kennedy; Nicolette C Ross; Kimberly M Lovell; Zhizhou Yue; Jenny Morgenweck; Michael D Cameron; Thomas D Bannister; Laura M Bohn
Journal:  Cell       Date:  2017-11-16       Impact factor: 41.582

3.  Structure-based discovery of opioid analgesics with reduced side effects.

Authors:  Aashish Manglik; Henry Lin; Dipendra K Aryal; John D McCorvy; Daniela Dengler; Gregory Corder; Anat Levit; Ralf C Kling; Viachaslau Bernat; Harald Hübner; Xi-Ping Huang; Maria F Sassano; Patrick M Giguère; Stefan Löber; Grégory Scherrer; Brian K Kobilka; Peter Gmeiner; Bryan L Roth; Brian K Shoichet
Journal:  Nature       Date:  2016-08-17       Impact factor: 49.962

4.  A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine.

Authors:  Scott M DeWire; Dennis S Yamashita; David H Rominger; Guodong Liu; Conrad L Cowan; Thomas M Graczyk; Xiao-Tao Chen; Philip M Pitis; Dimitar Gotchev; Catherine Yuan; Michael Koblish; Michael W Lark; Jonathan D Violin
Journal:  J Pharmacol Exp Ther       Date:  2013-01-08       Impact factor: 4.030

5.  Benefit and Risk Evaluation of Biased μ-Receptor Agonist Oliceridine versus Morphine.

Authors:  Albert Dahan; C Jan van Dam; Marieke Niesters; Monique van Velzen; Michael J Fossler; Mark A Demitrack; Erik Olofsen
Journal:  Anesthesiology       Date:  2020-09       Impact factor: 7.892

6.  Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists.

Authors:  Alexander Gillis; Arisbel B Gondin; Andrea Kliewer; Julie Sanchez; Herman D Lim; Claudia Alamein; Preeti Manandhar; Marina Santiago; Sebastian Fritzwanker; Frank Schmiedel; Timothy A Katte; Tristan Reekie; Natasha L Grimsey; Michael Kassiou; Barrie Kellam; Cornelius Krasel; Michelle L Halls; Mark Connor; J Robert Lane; Stefan Schulz; Macdonald J Christie; Meritxell Canals
Journal:  Sci Signal       Date:  2020-03-31       Impact factor: 8.192

Review 7.  Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics.

Authors:  Travis W Grim; Agnes Acevedo-Canabal; Laura M Bohn
Journal:  Biol Psychiatry       Date:  2019-10-31       Impact factor: 13.382

8.  Opioids depress breathing through two small brainstem sites.

Authors:  Iris Bachmutsky; Xin Paul Wei; Eszter Kish; Kevin Yackle
Journal:  Elife       Date:  2020-02-19       Impact factor: 8.140

9.  Drug and Opioid-Involved Overdose Deaths - United States, 2017-2018.

Authors:  Nana Wilson; Mbabazi Kariisa; Puja Seth; Herschel Smith; Nicole L Davis
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-03-20       Impact factor: 17.586

10.  The novel μ-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception.

Authors:  Rob Hill; Alex Disney; Alex Conibear; Katy Sutcliffe; William Dewey; Stephen Husbands; Chris Bailey; Eamonn Kelly; Graeme Henderson
Journal:  Br J Pharmacol       Date:  2018-05-14       Impact factor: 8.739

View more
  3 in total

Review 1.  Opioids and pituitary function: expert opinion.

Authors:  Mônica R Gadelha; Niki Karavitaki; Jeffrey Fudin; Jeffrey J Bettinger; Hershel Raff; Anat Ben-Shlomo
Journal:  Pituitary       Date:  2022-01-23       Impact factor: 4.107

2.  Optimization of a Pyrimidinone Series for Selective Inhibition of Ca2+/Calmodulin-Stimulated Adenylyl Cyclase 1 Activity for the Treatment of Chronic Pain.

Authors:  Jason A Scott; Monica Soto-Velasquez; Michael P Hayes; Justin E LaVigne; Heath R Miller; Jatinder Kaur; Karin F K Ejendal; Val J Watts; Daniel P Flaherty
Journal:  J Med Chem       Date:  2022-03-10       Impact factor: 8.039

3.  Mu-opioid receptor-dependent transformation of respiratory motor pattern in neonates in vitro.

Authors:  Maia G Gumnit; Jyoti J Watters; Tracy L Baker; Sarah M Johnson; Stephen M Johnson
Journal:  Front Physiol       Date:  2022-07-22       Impact factor: 4.755

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.